DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
BicycleTx Limited
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
EMD Serono
Aulos Bioscience, Inc.
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Gilead Sciences
University of Oklahoma
Gruppo Oncologico Italiano di Ricerca Clinica
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Emory University
EMD Serono
Massachusetts General Hospital
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
M.D. Anderson Cancer Center
University Health Network, Toronto
University of Iowa
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Maastricht University Medical Center
Centre Francois Baclesse
G1 Therapeutics, Inc.
Pfizer
VA Office of Research and Development
Queen Mary University of London
Jules Bordet Institute
Case Comprehensive Cancer Center
ImmunityBio, Inc.
SWOG Cancer Research Network
Memorial Sloan Kettering Cancer Center
Exelixis
EMD Serono
AdventHealth
Pfizer
Tulane University
University of Utah
Kyowa Kirin Co., Ltd.
Pfizer
Pfizer
University of Oklahoma
Brigham and Women's Hospital
Leap Therapeutics, Inc.
Associació per a la Recerca Oncologica, Spain
Fate Therapeutics
Erasmus Medical Center
Genome & Company